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The human cytosolic sulfotransfases (hSULTs) comprise a family of 12 phase II enzymes involved in the metabolism of
drugs and hormones, the bioactivation of carcinogens, and the detoxification of xenobiotics. Knowledge of the
structural and mechanistic basis of substrate specificity and activity is crucial for understanding steroid and hormone
metabolism, drug sensitivity, pharmacogenomics, and response to environmental toxins. We have determined the
crystal structures of five hSULTs for which structural information was lacking, and screened nine of the 12 hSULTs for
binding and activity toward a panel of potential substrates and inhibitors, revealing unique ‘‘chemical fingerprints’’ for
each protein. The family-wide analysis of the screening and structural data provides a comprehensive, high-level view
of the determinants of substrate binding, the mechanisms of inhibition by substrates and environmental toxins, and
the functions of the orphan family members SULT1C3 and SULT4A1. Evidence is provided for structural ‘‘priming’’ of
the enzyme active site by cofactor binding, which influences the spectrum of small molecules that can bind to each
enzyme. The data help explain substrate promiscuity in this family and, at the same time, reveal new similarities
between hSULT family members that were previously unrecognized by sequence or structure comparison alone.
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Introduction
Cytosolic sulfotransferases (SULTs) comprise a family of
enzymes that catalyze the transfer of a sulfonate group from
39-phosphoadenosine 59-phosphosulfate (PAPS) to an accept-
or group of the substrate (Figure 1). In doing so, SULTs
modulate the activities of a large array of small endogenous
and foreign chemicals, including drugs, toxic compounds,
steroid hormones, and neurotransmitters. Because sulfonated
molecules are highly soluble in water and easily excreted
from the organism, SULTs are often referred to as enzymes of
chemical defence. In some cases, however, SULTs activate
certain compounds from food and the environment into
mutagenic and carcinogenic metabolites [1].
To date, 13 human cytosolic sulfotransferase (hSULT)
genes have been identiﬁed; they partition into four families
[2,3]: SULT1, SULT2, SULT4, and SULT6. Although the
family members share considerable sequence and structural
similarity, they appear to have different biological functions.
The SULT1 family comprises nine members divided into four
subfamilies (1A1, 1A2, 1A3, and 1A4; 1C1, 1C2, and 1C3; 1B1;
and 1E1). The SULT1A3 and SULT1A4 genes appear to have
arisen from a segmental duplication and encode the same
protein [4]. Members of the SULT1 family have been shown to
sulfonate simple phenols, estradiol, and thyroid hormones, as
well as environmental xenobiotics and drugs. The SULT2
family has two genes, encoding three proteins (SULT2A1,
SULT2B1a, and SULT2B1b), which catalyze sulfonation of
hydroxyl groups of steroids, such as androsterone, allopreg-
nanolone, and dehydroepiandrosterone (DHEA). SULT4A1 is
the only member of the SULT4 family. The fact that it is
highly conserved and expressed primarily in the brain
suggests an important function; however, no activity or
function has been identiﬁed for this gene [5]. Finally the
SULT6B1 gene is expressed in the testis of primates, but
neither the protein nor its enzymatic activity has been
characterized [3].
Recent progress in the structural biology and character-
ization of the catalytic mechanism of hSULTs has established
that many family members have distinct, but overlapping,
substrate speciﬁcities and that the enzymes have a sequential
catalytic mechanism that is susceptible to substrate inhibition
[6,7]. Nevertheless, only a few of the human enzymes have
been subjected to detailed structural and mechanistic studies
[6,8–16], and there are no reports of a systematic comparison
among all the hSULTs. Understanding the structural and
mechanistic basis for speciﬁcity among hSULTs is essential to
elucidate their role in the metabolism of regulatory
hormones, drugs, and carcinogens, and may assist in chemical
risk assessment and the design of more-effective therapeutics.
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PLoS BIOLOGYHere we report the crystal structures of ﬁve of the 12
structurally unique hSULTs. These structures, combined with
those previously reported for six other hSULTs, allowed a
comprehensive comparison of both global and local struc-
tural features. We further screened nine hSULTs for binding
activity toward a set of 90 potential substrates and inhibitors,
and eight hSULTs for enzymatic activity toward 31 potential
substrates in order to better understand the relationship
between binding speciﬁcity, activity, and structure within the
hSULT family. These data, combined with detailed structural
analysis of substrate binding sites, reveal relationships
between family members not previously apparent from
sequence analysis. ‘‘Chemical ﬁngerprints’’ of the spectrum
of small molecules that bind in the presence and absence of
the cofactor product, 39-phosphoadenosine 59-phosphate
(PAP), demonstrate a marked change in the small molecule
binding proﬁle upon PAP binding. This result, combined with
the structural data, suggests PAPS has a strong inﬂuence on
which compounds may bind in the substrate binding site and
raises the possibility that the enzymes might be inhibited by
chemically related compounds that are not productive
substrates. The binding studies also provide insight into
potential functions of the under-characterized SULT1C
subfamily and of SULT4A1, an orphan member of the SULT
family expressed primarily in the brain.
Results
Completion of the Structural Coverage of hSULTs
The crystal structures of SULT1C3 bound to PAP, apo
SULT1C2, a ternary complex of SULT1C2 bound to PAP, and
the environmental toxin, pentachlorophenol (PCP), and
SULT4A1 were solved at 3.2, 2.0, 1.8, and 2.2 A ˚ , respectively
(Figure S1 and Table S1). We also recently reported the
structures of SULT1B1 and SULT1C1 bound to PAP at 2.1
and 1.8 A ˚ , respectively [17]. The structures of a single subunit
of each of these normally dimeric proteins are presented in
Figure 2 along with a representative structure of each of ﬁve
other SULT family members previously reported in the
literature [8,10–15]. Six additional SULT structures, which
are available in the Protein Data Bank, are presented in
Figure S2. As expected, all SULTs share the same basic fold: a
central four-stranded parallel b-sheet surrounded by a-
helices and three loops that are often disordered (dashed
lines) in the absence of PAP and/or substrate. These
disordered segments comprise a 13-residue loop (shown in
gold), a 4;10 residue loop (cyan), and a large 32;46 residue
loop (green and magenta). These loops have been mapped
onto the aligned protein sequences in Figure 3 using the same
colouring scheme. The degree of disorder and the exact
conformation of these loops vary considerably across the
family, but in general, the presence of ligands (cofactor and/
or substrate) is coupled with increased order, namely, the
formation of helices a4-a5 (gold), and a14-a15 (green). In
some cases, partial stabilization can be attributed to
molecular packing in the crystal, as in, for example, the
stabilization of a14 (green) in apo SULT1C2. The binding site
for PAP or PAPS (PAP(S)) is nearly identical in all structures
bound to these ligands, with highly conserved residues
contributing to the binding pocket (highlighted in red in
Figures 2 and 3). It is interesting to note that the SULT6B1
sequence in the protein databases lacks the N-terminal
region, which encodes a b-sheet thought to be an important
structural component of the SULT fold (Figure 3). We note
that the recombinant SULT6B1 did not express in our
attempts to purify it from bacteria.
Structural Comparison Supports a Role for PAPS in
Priming the Conformation of Substrate Binding Loops
It is generally agreed that sulfonation takes place via a
sequential mechanism in which a ternary enzyme complex is
ﬁrst formed, followed by reaction and release of products [7].
However, both random and ordered binding of the substrate
and cofactor molecules have been reported, and the detailed
kinetic mechanism (or mechanisms) of the sulfonate transfer
reaction is the subject of continuing research (reviewed in
[7]). Comparison of all the available structural data provides
insight into the order of substrate and cofactor binding. The
structures provide evidence for both binary complexes
(enzyme/substrate and enzyme/cofactor) consistent with a
random bi-bi mechanism and ruling out an ordered
mechanism in which binding of substrate requires binding
of cofactor (or vice versa). This is in agreement with a detailed
kinetic analysis for SULT1E1 [18]. However, a closer
inspection of the structures also suggests that binding of
Figure 1. Schematic of the Reaction Catalyzed by SULTs
doi:10.1371/journal.pbio.0050097.g001
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Author Summary
We metabolize many hormones, drugs, and bioactive chemicals and
toxins from the environment. One family of enzymes that participate
in the metabolic process consists of the cytosolic sulfotransferases,
or SULTs. SULTs have a variety of mechanisms of action—sometimes
they inactivate the biological activity of the chemical (e.g., in the
case of estrogen). At other times, the enzymes make the chemical
more toxic (e.g., for certain carcinogens). Humans have 12 distinct
SULT enzymes. Determining how each of these human enzymes
recognizes and distinguishes between the thousands of chemicals
we confront each day is essential for understanding hormone
regulation, assessing environmental risk, and eventually developing
better, more-effective drugs. We have studied the human SULT
family of enzymes to profile which small molecules are recognized
by each enzyme. We also visualized and compared the detailed
structural features that determine which enzyme interacts with
which molecule. By studying the entire family, we discovered new
ways in which chemicals interact with each enzyme. Furthermore,
we identified new inhibitors and inhibitory mechanisms. Finally, we
discovered functions for many of the human enzymes that were
previously uncharacterized.substrates may not be completely uncoupled from binding of
the cofactor. In all the structures with the co-factor product,
PAP, a14-a15, and the C-terminal segment of the largest
ﬂexible loop (green in Figure 2) are ordered. This region
contributes three absolutely conserved residues necessary for
PAPS binding, T228, R258, and G260 (SULT1A1 numbering
and red in Figure 2). Importantly, although the other loops
(cyan, gold, and magenta) do not contribute directly to PAPS
binding, they are more likely to be partially ordered in the
presence of PAP(S). The PAP(S)-induced ordering of a14-a15
and residues 256–262 (green and red) may also restrict the
conformations available to the intervening substrate-binding
magenta loop when PAP is bound. Thus, the structural data
suggest that PAPS binding tends to prime the cyan, gold, and
magenta loops for binding to the substrate.
On the other hand, the structure of SULT2A1 bound to
androsterone [13] (Figure 2L) hints that binding of substrates
does not prime the PAPS binding loops. In this structure, the
substrate-binding cyan and gold loops are ordered, but the
magenta loop and adjacent PAPS binding residues (green and
Figure 2. Representative Structures for Each of the hSULTs Grouped According to Similar Global Structural Features
Apo proteins with considerable disorder in several loops: (A) SULT1A3 (1CJM), (B) SULT1C2 (2AD1), and (C) SULT4A1 (1ZD1). Structures with increased
order due to binding of PAP (green helices, purple loop): (D) SULT1C1 (2ETG), (E) SULT1B1 (1XV1), and (F) SULT1C3 (2H8K). Ternary complexes display
further ordering of substrate binding loops: (G) SULT1A1 with PAP and p-nitrophenol (1LS6), (H) SULT1C2 with PAP and PCP (2GWH), and (I) 1E1 with
PAP and 3,5,39,59-tetrachloro-biphenyl-4,4’-diol (1G3M). Structures with unusual features that likely reflect catalytically unproductive proteins: (J)
SULT2A1 bound to DHEA, but without PAP (1J99); compare to (K) structure of the same protein with PAP (1EFH), and (L) with androsterone (1OV4). The
structures we solved are labelled with an asterisk. The question mark (?) indicates a helix formation, which leads to a non-productive conformation. The
Protein Data Bank code for each structure is shown in parentheses. The proteins are represented by a ribbon model; PAP and substrate are shown as
stick models coloured per element (carbon in yellow, oxygen in red, nitrogen in blue, and phosphate in magenta). The loops are coloured as discussed
in the text (gold, cyan, green, and purple).
doi:10.1371/journal.pbio.0050097.g002
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Human Cytosolic Sulfotransferasesred portion of the loop) are disordered. Thus, although in this
case, substrate and PAP(S) molecules can each bind inde-
pendently to the enzyme as in a random bi-bi mechanism,
there may be some degree of cooperativity between substrate
binding and prior cofactor binding, but not vice versa. Given
that the estimated cellular concentration of PAPS is well
above that of most substrates, this may be relevant to the
catalytic mechanism.
The family-wide structural comparison also suggests an
additional or alternative explanation for the well-docu-
mented substrate inhibitory effect. Previously reported cases
of substrate inhibition have been attributed either to two
substrate molecules occupying the active site at the same time
[8,19] or to the ability of substrates to bind in unproductive
orientations at higher concentrations [6,14]. Examination of
the structures in Figure 2 suggests a third or alternative
mechanism; at high concentrations, substrates may bind in a
mode in which the binding loops are incompatible with PAPS
binding. This case is exempliﬁed by the structure of SULT2A1
with DHEA [14]. As shown in Figure 2J, this structure can
accommodate two substrate orientations at roughly 308 to
one another. Comparison with other hSULT structures
strongly suggests that SULT2A1 in this structure adopts a
non-productive conformation. A portion of the green-and-
magenta loop that contributes two residues for PAP(S)
binding is folded into a helix, orienting the crucial PAPS
binding residues away from the cofactor binding pocket. This
helix conformation is not an intrinsic feature of SULT2A1,
because in the SULT2A1–PAP complex, this region adopts a
conformation similar to that in other SULT–PAP structures
(compare Figure 2K and 2J with this region highlighted by a
question mark). Thus, it appears that the structure adopted
by SULT2A1 with two molecules of DHEA is incompatible
with PAP(S) binding and that this conformation is induced by
the substrate. This is further evidence of ‘‘communication’’
between the substrate binding site and the PAPS binding site.
Ligand Binding and Activity Profiles Reveal Enzyme-
Specific Chemical Fingerprints
In order to predict and understand the fate of xenobiotics
and drug candidates in humans, it is essential to better
understand the selectivity and speciﬁcity of binding and
activity within the hSULT family. Although detailed analyses
of individual structures have been very informative in this
regard [6,8–12,16], we sought to compare all active sites
relative to the spectrum of small molecules that can bind to
each site. However, several of the proteins whose structures
were solved in this study have not been previously charac-
terized, and it was difﬁcult to directly compare data from the
literature due to differences in experimental conditions.
Therefore, in order to evaluate speciﬁcity and selectivity in a
consistent manner, nine puriﬁed, recombinant hSULTs were
screened for binding to a library of 90 small molecules (Table
S2) that comprised known substrates, inhibitors, related
hormones, bioamines, and drugs [20,21]. In order to proﬁle
the entire hSULT family, we made use of the well-known fact
that equilibrium binding of a ligand increases the thermal
stability of a protein in a manner proportional to the
concentration and binding afﬁnity of the ligand [20,21]. In a
multi-well format, the thermal stability of each hSULT was
monitored as a function of temperature and in the presence
or absence of compounds (Figure 4). In the absence of
compounds, well-behaved, sigmoidal thermo-denaturation/
aggregation proﬁles were obtained for hSULTs 1A1, 1A3,
1B1, 1E1, 1C1, 1C2, 1C3, 2A1, and 4A1. SULT2B1b did not
denature within the range of temperature used for this type
of analysis (up to 80 8C). In this screening format, compounds
that stabilize a protein by more than 28 C are scored as
positives (Table 1). It was not possible to assay binding to
ligands in the presence of the sulfonated co-factor, PAPS,
because the sulfonate transfer reaction would have taken
place. However, except for SULT4A1, PAPS and PAP had
equivalent stabilizing affects on all hSULTs. Thus, PAP was
used as a substitute for PAPS in considering the effect of
cofactor upon substrate binding, and screens for the binding
of ligands were performed in the absence and presence of a
saturating amount of PAP.
Based on these binding results, a set of 20 compounds that
bound to at least one hSULT plus 11 additional related
compounds or known substrates were used as a pool of
potential substrates for enzymatic activity of hSULTs 1A1,
1A3, 1B1, 1C1, 1C2, 1C3, 1E1, and 2A1 (Table 2). We
monitored the conversion of PAPS to PAP by high-perform-
ance liquid chromatography (HPLC) as a tractable method of
screening multiple proteins against multiple substrates (eight
proteins and 31 substrates in this study), and the results serve
as a convenient ﬁrst approximation of enzymatic activities.
We note that due to the relatively low sensitivity of this
method, we were not able to reliably assay substrates at
nanomolar concentrations, and therefore, some of the results
may be complicated by substrate-mediated inhibition. In-
deed, inspection of Table 2 shows that in some cases, the
highest levels of activity were observed at lower substrate
Figure 3. Sequence Alignment of hSULTs Showing Structural Features with Colour Coding Corresponding to That of the Structures in Figure 2
doi:10.1371/journal.pbio.0050097.g003
Figure 4. Thermo-denaturation/Aggregation Profile of SULT2A1
The intensity of scattered light is plotted as a function of temperature (T)
for SULT2A1 in the absence of any ligand (filled diamond), and in the
presence of AMP-PNP (filled square), lithocholic acid (open triangle), PAP
(filled triangle), and both PAP and dehydroisoandrosterone 3-sulfate
(open circle). The inflection point of the denaturation curve is taken as
Tagg as reported in Table 1.
doi:10.1371/journal.pbio.0050097.g004
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Human Cytosolic Sulfotransferasesconcentrations. This is especially true of SULT1A1, an
enzyme for which signiﬁcant substrate inhibition has been
noted previously [8].
The combined ligand binding and activity screens revealed
a unique ‘‘chemical ﬁngerprint’’ for each hSULT (Tables 1
and 2). First, as expected from previous studies, there was
considerable overlap in the substrate speciﬁcity for enzymatic
activity. For example, all hSULTs assayed here were able to
sulfonate a number of phenolic compounds such as naphthols
and/or alkylphenols. However, within each substrate proﬁle,
there were also elements of speciﬁcity. For example,
SULT1A1 and SULT1A3 were the only two hSULTs that
showed signiﬁcant activity toward catecholamines compared
to other substrates, with SULT1A3 being more speciﬁc for
dopamine, as expected from previous studies [22–26].
SULT1A3 was also the only protein to bind dopamine in
the binding assays, consistent with its designation as human
dopamine sulfotransferase [25]. It is interesting to note that
in the past, SULT1A1 and 1A3 have been distinguished from
one another in tissue fractions by the higher sensitivity of
SULT1A1 to inhibition by 2,6-dichloro-4-nitrophenol
(DCNP) [27]. Although we did not measure inhibition by this
compound, we note that SULT1A1 bound DCNP in the
presence of PAP, whereas SULT1A3 did not (Table 1).
Six hSULTs (1C1, 1C2, 1E1, 1B1, 1A1, and 1A3) had
enzymatic activity toward resveratrol, a polyphenolic com-
pound present in grapes and wine, with possible anticancer
and cardioprotective activities [28]. The activity proﬁles for
resveratrol also displayed evidence of substrate inhibition by
this compound for SULTs 1C1, 1C2, 1A1, and 1E1. Acet-
Table 2. Sulfotransferase Activity Screen of hSULTs
Category Substrate Sulfotransferase Activity (nmol/min/mg)
SULT1C1 SULT1C2 SULT1C3
Substrate concentration
(lM)
10 25 100 10 25 100 10 25 100
Catecholamines Dopamine N N N N N N N N N
Epinephrine N 0.1 0.1 NN 0.8 NNN
Norepinephrine N 0.1 0.1 N NNN N N
Isoprenaline N N N N N 0.8 NNN
Steroid-/large/fused ring 17a-Ethinylestradiol N N N N N N N N N
2-Hydroxyestradiol N N 0.1 N NNN N N
Lithocholic acid N N N N N N 0.6 0.8 1.1
a-Zearalenol 0.3 0.6 1.5 2.0 8.1 9.3 1.1 2.7 4.1
T2 (3,5-diiodo-L-
thyronine)
NN0.1 N NNN N N
T3 (3,39,5-triiodo-L-
thyronine)
0.4 0.6 1.1 NN 2.9 NNN
T4 (3,39,5,59-tetraiodo-
L-thyronine)
0.3 0.5 0.8 N NNN N N
Cholesterol N N N N N 0.7 NN0.4
Estrone 0.1 NN NN 0.8 NNN
Minoxidil N N N N N N N N N
Salbutamol N N N N N N N N N
Phenols 4-Aminophenol N N N 1.3 1.2 2.6 NNN
1-Naphthol 0.1 0.1 0.6 4.6 11.7 31.5 0.7 1.2 1.8
2-Naphthol 0.2 0.3 1.1 3.3 16.2 11.7 NNN
2-Ethylphenol N N N 1.4 4.8 25.8 0.9 1.4 2.2
4-Ethylphenol N N 0.1 1.8 9.9 39.5 NNN
2-n-Propylphenol N N 0.1 0.8 3.4 15.5 N 0.7 0.9
2-sec-Butylphenol 0.3 NN 1.2 NNN 1.0 2.1
4-n-Amylphenol 0.1 0.1 0.3 N 6.4 17.2 NN0.3
4-n-Heptylphenol N N N N N N N N N
4-Nitrophenol 0.3 0.5 1.9 N8 . 533.4 NN0.6
Vanillin 0.3 0.8 2.5 5.2 15.8 23.0 NN0.8
1,2,3,4-Tetrahydro-
1-Napthol
N N N N NNN 0.3 0.8
p-Cresol N N 0.1 4.9 17.7 40.7 NNN
Acetaminophen
(Paracetamol)
NN0.1 4.8 8.6 22.6 NNN
Tyramine N N N 3.1 9.0 38.2 NNN
Resveratrol 0.3 0.5 0.3 3.4 15.0 5.2 N N N
Background 0.25 6 0.01 6.2 6 0.6 0.9 6 0.2
Enzymatic activities of the eight hSULTs were assayed at concentrations of 10, 25, and 100 lM of each substrate as described in Material and Methods. The first row indicates the
concentration of each substrate in lM in each set of experiments. The last row indicates the background rate of conversion of PAPS to PAP in the presence of enzyme, but absence of any
substrate. The error in the background rate is the standard deviation of three measurements. All other numbers in the table are the activity in nmol/min/mg of protein after subtracting
the background rate. For a given enzyme/substrate pair, the substrate concentration that exhibited the highest activity is highlighted in blue. Activity values between one and two
standard deviations of the background rate are highlighted in red. Those above two standard deviations are in green.
N, not detected.
doi:10.1371/journal.pbio.0050097.t002
PLoS Biology | www.plosbiology.org May 2007 | Volume 5 | Issue 5 | e97 1069
Human Cytosolic Sulfotransferasesaminophen was a substrate for SULTs 1A1, 1E1, 1A3, 1C2,
and 1B1, but not SULT1C3 and SULT2A1. Substrates for
SULT1C3 have not been reported previously. Our data
indicate that this recently identiﬁed member of the hSULT
family is able to sulfonate p-nitrophenol, 1-naphthol, 2-
ethylphenol, 2-n-propylphenol, and 2-sec-butylphenol, as well
as the steroid-related compounds, a-zearalenol and litho-
cholic acid. SULT1C3 appeared to be most active with a-
zearalenol (4.1 nmol/min/mg) and 2-ethylphenol (2.2 nmol/
min/mg). These data suggest SULT1C3 may contribute to the
metabolism of steroid and phenolic compounds. Finally,
SULTs 2A1 and 1E1, which are reported to metabolize
steroids [29–32], both bound to and sulfonated multiple
steroid and steroid-like compounds with different apparent
speciﬁcities. These data show that despite the limitations of
our rapid screening method, the enzymatic activity data in
Table 2 reﬂects, to a ﬁrst approximation, the expected
relative substrate activities reported in the literature and
reveal new activities toward pharmacologically important
compounds. The binding data, on the other hand, suggest a
more complicated situation.
PAP Is Able to Alter Ligand Binding Profiles
The ligand binding proﬁles were remarkably different in
the presence and absence of PAP (with the exception of
SULT4A1, which will be discussed separately below). Some
known substrates for the well-characterized SULTs appeared
to bind only in the presence of PAP—for example, dopamine
for SULT1A3 [24,25], and 1-naphthol for SULT1B1 [33]—
whereas many previously unreported compounds bound to
these and other family members in the absence of PAP. It is
interesting to note that not all known substrates, nor all of
those with reactivity in our activity screens, were found to
bind to the enzyme in the presence of PAP. For example,
resveratrol was a substrate for SULT1A3 and SULT1C2, but
did not stabilize either protein in the binding assays, either in
the presence or absence of PAP. There are several reasons
that may account for these observations. First, the enzymatic
screen is likely more sensitive than the ligand binding assay in
which compounds with Km or Kd values in the high micro-
molar range are less likely to be detected [20,21]. Second,
some ternary complexes may not be signiﬁcantly stabilized
relative to the PAP–enzyme complex (especially at elevated
Table 2. Extended.
Sulfotransferase Activity (nmol/min/mg)
SULT1B1 SULT1A1 SULT1A3 SULT2A1 SULT1E1
10 25 100 10 25 100 10 25 100 10 25 100 10 25 100
NN0.6 2.3 5.2 13.4 7.4 25.7 74.4 NNN N N 0.7
NN1.2 1.8 2.9 8.0 N 0.5 6.0 NNN N N N
NN0.5 1.7 1.7 4.2 0.7 2.7 16.9 NNN N N 0.7
N 0.6 1.1 2.7 6.1 13.6 5.1 16.6 54.0 NNN N N 0.8
NNN 2.5 7.2 NNN1.4 1.4 1.6 1.3 1.2 4.3 13.3
NN0.5 1.0 1.8 3.1 NNN1.0 1.5 3.1 NNN
N N NNNNNNN2.7 8.3 11.4 NNN
0.8 1.5 1.1 6.3 16.9 25.9 0.8 2.9 5.5 NNN 2.5 7.1 13.0
NNN 1.0 NNNNN0.3 0.6 1.2 NNN
NN0.9 1.1 1.2 NN0.5 1.5 NN0.3 2.0 2.2 4.4
NN2.5 NNNNN0.6 NN1.6 N 1.2 2.1
NNN 0.8 NNNNNN N NNNN
NNN 5.2 4.9 5.0 NNN0.3 1.1 1.1 N 0.8 3.4
NN1.6 1.6 NNNNNN N NN0.9 1.9
NNN 0.9 1.3 N 1.2 2.7 12.7 N 0.3 NNNN
N 0.7 1.7 9.2 16.4 4.7 NNNN N NNN1.2
2.4 5.9 15.3 8.8 6.7 4.1 9.5 24.7 68.5 N 0.4 1.0 5.0 9.6 26.0
2.9 8.9 16.8 11.1 16.8 10.0 10.0 20.3 42.6 N 0.2 0.8 16.6 41.5 57.9
2.1 5.5 16.5 10.3 10.4 4.9 1.2 4.7 15.2 NN0.2 2.5 5.3 15.7
1.7 4.0 9.9 4.8 63.0 25.3 0.5 1.3 4.3 NNN 9.4 21.9 38.2
2.1 5.2 14.2 10.0 15.4 8.2 1.0 2.8 11.0 NNN 1.8 4.6 12.7
NN1.1 1.0 1.2 1.2 N 1.4 1.2 NNN N N N
0.7 2.2 6.2 5.4 12.5 24.3 1.5 2.4 4.7 N 0.4 1.3 2.6 5.7 20.0
NN0.5 0.7 2.6 1.6 NN0.8 NN0.2 NN1.0
1.6 5.3 13.2 4.3 21.4 7.2 N 1.7 4.1 N 0.2 0.3 2.4 5.3 16.8
2.6 8.2 19.0 NNN11.7 29.4 64.0 N 0.3 0.5 5.4 12.2 25.1
0.9
1.6 3.4 1.3 1.1 NNNNN N 0.9 NNN
3.4 9.2 16.3 11.3 28.5 16.7 1.3 3.4 9.5 NN0.3 4.0 9.2 26.8
N 0.6 1.1 3.0 5.4 14.1 N 0.7 3.8 NNN 1.5 3.6 11.6
2.1 5.7 13.0 0.9 0.9 1.2 1.0 1.9 7.5 NNN 1.4 4.5 12.2
2.9 6.9 18.4 7.4 3.6 1.0 5.4 16.6 26.1 NNN 15.8 36.6 10.3
1.3 6 0.4 5.4 6 0.3 6.8 6 0.4 2.1 6 0.1 1.7 6 0.5
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Human Cytosolic Sulfotransferasestemperatures). Finally, the presence of the sulfonate group of
PAPS may also contribute to binding of substrates, and these
cases may not be detected in our binding assay. Interestingly,
binding of SULT1C1, 1B1, and 1E1 to resveratrol was only
observed in the absence of PAP, but all are active toward this
substrate. Nevertheless, the radically different binding pro-
ﬁles observed in the presence and absence of PAP are
consistent with the structure-based mechanisms proposed
above. Speciﬁcally, PAP (and presumably PAPS) appears to
prime the substrate binding loops for subsequent binding to
certain substrates, whereas in the absence of cofactor, the
loops are free to bind alternative ligands (perhaps only at
high concentrations), or non-productive ligand-bound con-
formations may exist. This priming of the substrate binding
loops is likely made possible by ﬂexibility of the binding loops
observed in the structure. This structural plasticity may allow
a reconﬁguration of substrate binding loops in the absence of
PAP(S) in order to bind a different chemical class of
compound. For example, both SULT1C3 and SULT1B1 were
stabilized by catecholamines in the absence of PAP, but
neither showed signiﬁcant activity toward this class of
compounds. This raises the possibility that certain endoge-
nous and/or exogenous compounds, such as those that bind in
the absence of PAP, may act as competitive inhibitors of
SULTs by occupying the substrate binding pocket and
preventing a productive PAPS binding conformation, as for
SULT2A1 (Figure 2J).
Screening and Structural Analysis Reveals Novel
Mechanism of Inhibition
Excluding SULT4A1, three compounds bound to all
hSULTs: adenosine 59-(b,c-imido) triphosphate (AMP-PNP),
a non-hydrolysable ATP analog; pyridoxal 5-phosphate (PLP),
a competitive inhibitor for sulfotransferases [34]; and
quercetin, a potent inhibitor of SULT1A1 and SULT1E1
[35]. These compounds had been known to inhibit one or
more sulfotransferases, but our data suggest that they may be
universal SULT inhibitors. AMP-PNP and PLP bound only in
the absence of saturating amounts of PAP, suggesting that
they occupy the PAP binding site, as might be expected from
their structural similarity to PAP. Quercetin, found in many
fresh fruits and vegetables, is a ﬂavonoid with anti-tumour
and anti-inﬂammatory activities. It is possible that some of its
favourable physiological effects may be related to inhibition
of hSULT activity. Additional inhibitors bound to only a
subset of the hSULTs, including 3,5-dibromo-4-hydroxy-
benzoic acid (6,8-dichloro-4-oxo-4H-chromen-3-ylmethylene)
hydrazide (DBHD), 3,5-dibromo-4-hydroxy-benzoic acid (6-
chloro-4-oxo-4H-chromen-3-ylmethylene)-hydrazide
(DBHM), and PCP.
The binding proﬁles in Table 1 raise the possibility that
compounds that bind to hSULTs only in the absence of PAP
may inhibit hSULT activity. In order to investigate this
possibility, we assayed the activity of SULT1B1 in the
presence of increasing concentrations of ﬁve compounds
found in our screens. These ﬁve include known inhibitors
(quercetin, DBHD, PLP, and PCP), as well as isoprenaline,
which binds to SULT1B1 only in the absence of PAP and is a
poor substrate for this enzyme (Tables 1 and 2). As shown in
Figure 5, PCP and DBHD were strong inhibitors of SULT1B1,
whereas PLP and quercetin had intermediate effects. Iso-
prenaline, however, had no inhibitory effect on the activity of
SULT1B1 with 1-naphthol, and it was sulfonated by SULT1B1
(Table 2), indicating that not all compounds that bind in the
absence of PAP are necessarily inhibitors.
PCP is a signiﬁcant environmental toxin due to its common
use as a wood preservative and its use in the pulp and paper
industry. Its chemical structure is related to hydroxylated
metabolites of polychlorinated biphenols (OH-PCBs) whose
endocrine-disruptive properties may be related to the
inhibition of estradiol sulfonation by SULT1E1 [36]. The
mechanism of inhibition of SULT1E1 by OH-PCBs and
related compounds has been proposed to take place via both
allosteric [36,37] and competitive [12,37] mechanisms. Our
binding data suggest that PCP may be a competitive inhibitor
of SULTs 1B1, 1C2, and 1A1 (Table 1). For 1C2 and 1A1, PAP
Figure 5 Inhibitory Effect of Isoprenaline, PLP, Quercetin, DBHD, and PCP
on Sulfotransferase Activity of SULT1B1 with 1-Naphthol as Substrate
Sulfotransferase activity of SULT1B1 at different concentrations of each
compound (5 to 312 lM) has been assayed as described in Materials and
Methods. Isoprenaline is indicated by a filled diamond, PLP by an open
circle, quercetin by a filled square, DBHD by a filled triangle, and PCP by a
filled circle.
doi:10.1371/journal.pbio.0050097.g005
Figure 6. The Superimposition of the Active Sites of the SULT1E1-PAP-
17b-estradiol Complex (1AQU) and the SULT1C2-PAP-PCP Complex
(2GWH)
The SULT1E1-PAP-17b-estradiol complex is shown in yellow, and the
SULT1C2-PAP-PCP complex is shown in grey. The PCP (chlorine atoms in
green) and 17b-estradiol (EST) molecules are highlighted along with the
catalytic His115 and PAP. See text for discussion.
doi:10.1371/journal.pbio.0050097.g006
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Human Cytosolic Sulfotransferaseswas required for binding; and for 1B1, PCP binds much better
in the presence of PAP, suggesting that PCP binds in a
substrate-like conformation facilitated by PAP(S). In order to
better understand the mechanism of inhibition by PCP, we
determined the structure of SULT1C2 bound to PAP and
PCP (Figure S3). The structure reveals that the protein
undergoes a disorder–order transition upon PCP and PAP
binding. Helices a4, a5, and aı5, and loops a5-a6 and a15-a16
are ordered only in the ternary complex, but not in the apo
SULT1C2 structure (Figure 2B and 2H). PCP is found in the
substrate binding pocket and therefore appears to be a
competitive inhibitor, consistent with crystallographic anal-
ysis of SULT1E1 bound to PAP and 3,5,39,59-tetrachlorobi-
phenol [12]. Comparison of the SULT1C2-PAP-PCP and
SULT1E1-PAP-estradiol structures (Figure 6) revealed two
structural features that may be relevant in explaining the
mechanism of PCP inhibition. In the co-crystal structures, the
phenol moieties of PCP and estradiol share the same relative
position and orientation, positioning the phenolic OH within
hydrogen-bond distance of the catalytic histidine. This
histidine is thought to be deprotonated and made catalyti-
cally competent to accept the phenolic hydrogen from
estradiol, facilitating nucleophilic attack on the sulfonate of
PAPS. Our structure shows that PCP appears to be in a
catalytically competent conformation. However, PCP and
estradiol differ dramatically in the acidity of their hydroxyl
groups; the estimated pKa for estradiol is approximately 15,
whereas that for PCP is 4.5. Thus, although PCP appears to
bind in a catalytically competent conformation, the phenolic
oxygen of PCP may be too weak a nucleophile to attack the
sulfonate of PAPS.
The inhibitory effects of OH-PCBs and PCP have been
interpreted previously in terms of variations in the bound
conformation of the halogenated compounds relative to that
of estradiol [12,36]. Although steric and conformational
factors clearly play a role, our structure of SULT1C2 with
PCP and PAP suggests a key role for the electronic nature of
the halogenated phenols. We examined the calculated pKa
values for the series of 21 4-hydroxyl–substituted PCBs for
which Kester et al. [36] reported 50% inhibitory concen-
tration (IC50) values. The results show a strong correlation
between the calculated acidity of these phenols with IC50
values, with the most acidic compounds having the strongest
inhibitory effect (Figure S4).
SULT4A1 Is an Atypical SULT with an Atypical Structure
Under the conditions of our screens, PAP bound to all
hSULTs except for SULT4A1. In order to rule out the
possibility that SULT4A1 simply has a much weaker afﬁnity
for PAP, we performed titration experiments for several of
the proteins with increasing concentrations of PAP ranging
from 90 lM to 90 mM (Figure 7A). SULT1C1, SULT1C2,
SULT1C3, and SULT1B1 showed similar saturation binding
curves, reaching saturation at about 100 lM. However, PAP
when added at concentrations as high as 90 mM did not
stabilize SULT4A1. SULT4A1 is one of the hSULTs that is
most divergent in sequence, and examination of the binding
pocket revealed two signiﬁcant differences that are predicted
to affect PAP binding. First, a Trp in a3 that is conserved in
all other hSULTs and stacks with the adenine ring of PAPS
(Trp53 in SULT1A1) is replaced with a Leu in SULT4A1
(Figure 3). Second, the magenta PAP binding loop is much
shorter in SULT4A1 than in the other hSULTs, and lacks the
conserved Lys residue that separates the key PAPS binding
residues Arg258 and Gly260 (SULT1A1 numbering), which
results in these residues being out of register. Taken together,
SULT4A1 has a slightly smaller PAPS binding pocket that is
p r e d i c t e dt ob eu n a b l et oa c c o m m o d a t et h ec o f a c t o r .
Interestingly, some residual electron density was observed
in the PAP binding pocket of recombinant SULT4A1.
Presumably this derives from a bound small molecule that
was co-crystallized, although we were not able to identify it
either by modelling atoms into the electron density or using
mass spectrometry.
To test the possibility that SULT4A1 might use an alternate
sulfonate donor, we tested several potential alternates such as
adenosine phosphosulfate, 4-nitrocatechol sulfate, 4-acetyl-
phenyl sulfate, estrone 3-sulfate, indoxyl sulfate, and 4-
methylumbelliferyl sulfate. None of these compounds stabi-
lized SULT4A1 against thermal aggregation (unpublished
Figure 7. SULT4A1 Does Not Bind PAP
(A) Thermal aggregation temperatures for SULT1B1 (filled circle), SULT1C3 (filled triangle), SULT1C1 (filled diamond), SULT1C2 (filled square), and
SULT4A1 (open circle) as a function of PAP concentration. PAP provides no stabilizing effect to SULT4A1.
(B) Superimposition of the PAP binding site of SULT1C1 (green) and SULT4A1 (yellow). A conserved Trp residue (W53 of SULT1C1; green ring in the
middle of figure, indicated by a red arrow) normally forms p-p stacking interactions with the adenine ring of PAP (blue) and hydrogen bonds to a
neighbouring conserved Thr (T228 in SULT1C1). SULT4A1 is the only SULT to have a Leu instead of Trp at this position. The Leu residue cannot make
stabilizing interactions with Thr or the adenine ring, and its position would cause a severe steric clash with PAP and PAPS.
doi:10.1371/journal.pbio.0050097.g007
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have signiﬁcant catalytic activity in vivo. Indeed, although
very weak activity has been reported in one case [38], other
groups have failed to observe activity for human SULT4A1
[5,39]. Signiﬁcantly, this protein, which is expressed primarily
in the brain, binds to 2-hydroxylestradiol, thyroid hormone,
T4 (3,39,5,59-tetraiodo-L-thyronine), and the catecholamines
norepinephrine, epinephrine, and isoprenaline (but not
dopamine), suggesting that SULT4A1 may modulate the
bioactivity of these compounds via a mechanism distinct
from sulfonation. Of note, SULT4A1 did not bind any simple
phenolic compounds under the conditions tested here.
Binding Profiles Suggest Alternative Classifications of
hSULTs
Examination of the chemical ﬁngerprints reﬂected in
Tables 1 and 2 suggests that subsets of the hSULTs can be
clustered based on the chemical properties of the compounds
that they bind—relationships that are not evident from global
sequence comparison. To explore alternative activity or
structure-based classiﬁcations of hSULTs in more detail, we
performed average hierarchical clustering on the experimen-
tal data in an attempt to identify correlations between the
local sequence or structural features of the substrate binding
pockets and activity proﬁles among the hSULTs. Figure 8
Figure 8. Average Linkage Hierarchical Clustering of SULTs
Clustering is shown according to (A) global sequence similarity, (B) local sequence of the substrate binding site, (C) local structure of the substrate
binding site, (D) catalytic activity profiles, (E) small molecule binding profiles in the presence of PAP, and (F) small molecule binding profiles in the
absence of PAP. The value under each clustering (c) is the correlation between the original data matrix and the cophenetic matrix—a matrix whose
elements represent the height at which these elements first meet in the tree. The higher this correlation, the more accurate the tree represents the
original data. See Materials and Methods for further details.
doi:10.1371/journal.pbio.0050097.g008
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eter, viewed using trees. Considering only global sequence
similarity, the hSULTs cluster according to their nomencla-
ture and phylogenetic relationships (Figure 8A). Considering
only the nine proteins for which we have binding or
enzymatic data, SULTs 1A1 and 1A3 are most closely related,
with a global sequence identity of 95%. The three SULT1C
proteins cluster with average sequence identities close to
55%, as do SULT1E1 and 1B1. SULT2, 4, and 6 subfamilies
are relative outliers with sequence identities to all other
SULTs considered here around 35% or less. It is well known
that related enzymes with sequence identities below 40%
have often evolved to have different substrate speciﬁcities
[40], and therefore, we would expect most of the SULTs to
sulfonate different substrates, except perhaps 1A1 and 1A3.
In keeping with this concept, the closely related SULTs 1A1
and 1A3 are clearly the most similar within the substrate
binding site, as measured by both local sequence and
structure comparisons (Figure 8B and 8C). However, the
clustering of the other more distantly related SULTs is
sufﬁciently different at the level of local sequence and
structure, such that the SULT1C proteins are no longer
clustered together and the outliers are different. These
comparisons show that the local sequence and structures of
the substrate binding sites do not correspond to the global
sequence relationships.
These results also illustrate why members of the same
subfamily do not metabolize the same classes of compounds.
Although the clustering of hSULTs presented here is likely
inﬂuenced by the limited subset of compounds used in our
binding and activity assays, the results provide an initial view
of the family-wide activity-based classiﬁcations. The trees that
cluster the eight or nine proteins according to their binding
and activity proﬁles (Figure 8D–8F) show a remarkably
different clustering from the sequence- and structure-based
trees. First, 1A3 and 1A1 no longer cluster together, despite
their strong global sequence similarity (95% identity).
Inspection of Table 1 shows that 1A1 strongly binds most of
the phenols and acidic compounds, once PAP is bound,
whereas 1A3 shows absolutely no binding of these substrates.
These SULTs are also distinguished by their differential
reactivity toward catecholamines, with SULT1A3 able to bind
dopamine and having higher relative activity toward cat-
echolamines compared to phenols, as previously noted [28].
Comparison of the residues in the substrate binding loops of
SULT1A1 and SULT1A3 revealed that all residues are
identical (and in identical positions in the structures) except
for the eight residues shown in Figure 9. These changes map
to two loops (residues 84–89 and 143–148) and residue 247
(SULT1A1 numbering). Importantly, SULT1A3, which does
not bind acidic compounds, has acidic instead of hydro-
phobic residues at three of these positions. The net result is a
much more negatively charged pocket for SULT1A3 com-
pared to SULT1A1. This difference would disfavour binding
of compounds with a net negative charge to SULT1A3 and
favour interactions with the amino group of catecholamines.
Thus, the strong local sequence and structure similarities in
1A1 and 1A3 are manifested in their similar ability to bind
similar inhibitors and sulfonate catecholamines (as a class),
but small, local sequence changes in the substrate binding site
have enhanced the ability of SULT1A3 to bind catechol-
amines such as dopamine [28], and completely changed its
ability to bind acidic compounds. The inﬂuence of residue
146 on the speciﬁcity of SULT1A1 compared to SULT1A3
(Ala vs. Glu) has been previously noted [28]; however, the
results presented here suggest that additional differences in
the binding loops also contribute to speciﬁcity.
SULT1B1 and 1C2 cluster together in the trees of local
structure, activity, and binding in the presence of PAP. These
groupings reﬂect their common ability to bind acidic
Figure 9. Binding Site Comparison of SULT1A1 Bound to PAP and p-Nitrophenol (1LS6) and SULT1A3 Bound to PAP and Dopamine (2A3R)
The side chains of the eight binding-site residues that differ between these two proteins are shown in yellow (SULT1A1) and red (SULT1A3).
doi:10.1371/journal.pbio.0050097.g009
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nitrophenol), with promiscuous activity proﬁles toward
phenols. Thus, SULT1B1 and 1C2 appear to be much more
closely related in terms of structure and activity than their
global sequences would indicate.
Finally, Figure 8F shows that the clustering of hSULTs
again differs when considering the binding of compounds in
the absence of PAP. In this case, none of the previously noted
similarities is evident. Many of the compounds in Table 1 are
inhibitors of hSULT activity. The differential clustering in
the absence of PAP may reﬂect possible unrelated conﬁg-
urations of binding-site residues when bound to these
compounds or the tendency for more disorder in the
absence of PAP. The clustering of both binding proﬁles
(Figure 8E and 8F) places SULT4A1 as the furthest outlier,
analogous to its position in the global sequence comparison.
Although this is consistent with the inability of SULT4A1 to
bind PAP and catalyze sulfonation, it is interesting to note
that this is not due to a radical difference in local binding-
site sequence or structure, because SULT4A1 clusters with
SULT1C1 when considering these local factors (Figure 8B
and 8C). As noted above, apparently small differences of one
to two residues in the PAP binding site are likely responsible
for this behaviour.
Discussion
An important challenge in structural biology, chemical
biology, and drug discovery is to relate changes in local
sequence and structure to the binding and activity proﬁles of
homologous enzymes in order to better predict or explain
substrate and inhibitor speciﬁcity within an enzyme family. In
thecaseofthehSULTs,thisisparticularlydesirableinorderto
predictthefateofxenobiotics,hormones,anddrugcandidates
in humans. Like other phase II detoxiﬁcation enzymes,
hSULTs are known to have broad and overlapping substrate
speciﬁcities. We and others have shown that this promiscuity
derives from the considerable ﬂexibility or plasticity of the
hSULT binding sites and therefore, a full understanding of
speciﬁcity will require multiple three-dimensional structures
for each hSULT in complex with substrates and inhibitors, as
well as knowledge of the full spectrum of small molecules that
bind in both productive and non-productive conformations.
Our structural and chemical proﬁling data prepare the
foundation for such detailed studies.
Here we also reveal a previously unrecognized structural
role for the cofactor PAP(S); namely priming of the often
disordered substrate binding loops for interaction with
substrates. The ‘‘magenta loop’’ (Figure 2), which contributes
to both PAPS and substrate binding pockets, can also, in some
instances, adopt an inactive conformation and may explain
substrate-induced inhibition and/or inhibition by compounds
that bind in the absence of PAPS, as well as by known
inhibitors. The ﬂexibility of the substrate binding loops in
hSULTs likely contributes to the wide repertoire of com-
pounds that can be accommodated in the substrate binding
pocket, only a subset of which lead to productive sulfonation.
Our results provide insight into mechanisms of inhibition
of hSULTs. In addition to structural mechanisms of substrate
inhibition (above), we identiﬁed three compounds (PLP,
AMP-PNP, and quercetin) that appear to be broad-spectrum
hSULT inhibitors, and may also inhibit other non-cytosolic
sulfotransferases. We have also provided insight into how
PCP and possibly other polychlorinated phenolic compounds
can inhibit hSULTs. These compounds, which are known
endocrine disruptors, appear to bind in a manner very
similar to other productive substrates, but are unreactive, at
least in part, due to their weakly acidic properties.
Our analyses have also provided insight into the functions
of the less well-characterized SULT1C subfamily and SUL-
T4A1. We have identiﬁed a number of novel substrates,
inhibitors, and compounds that bind to these SULTs in the
absence of PAP. These data combined with activity assays
revealed that SULT1C3 can bind catecholamines and phe-
nolic compounds, but only the latter are substrates. SULT4A1
is inactive as an enzyme in our experiments, likely due to its
inability to bind PAPS or other sulfonate donors. This orphan
SULT likely has an important function in the brain, never-
theless, because it is highly conserved and binds well to the
neurotransmitters epinephrine and norepinephrine.
The approach outlined here in which simple, medium
throughput binding and activity screens can be used to
proﬁle properties of puriﬁed enzymes has proven extremely
useful for identiﬁcation of novel substrates and analysis of
speciﬁcity across a human protein family. We demonstrate
that the relationship between sequence/structure and func-
tion within this small family is remarkably complex, and
differences in activity can reﬂect just a few amino acid
changes at critical locations within the protein’s active site.
Global sequence/structure comparisons provide good clues
for broad functional classiﬁcation, but cannot simply deﬁne
an enzyme’s cognate substrate or class of substrates. For the
sulfotransferases, which have a large and ﬂexible binding site,
it is clearly necessary to perform much more detailed studies
to understand both the binding and catalytic activities in
terms of local structure. The actual cellular activity of
hSULTs will depend on the spectrum of compounds available
to a given enzyme and their relative concentrations. The
tissue-speciﬁc and developmental variation in both hSULT
expression and the cellular milieu of small molecules
complicates further attempts to predict activities. Ultimately,
detailed enzymatic characterization of all puriﬁed hSULTs, as
well as cellular assays, will be needed to fully understand this
family. The data presented here form a basis for further
detailed biochemical and structural studies of both active and
inactive enzyme–small molecule complexes in order to fully
understand the role of hSULTs in the metabolic fate of
endogenous substrates, as well as drugs and toxic compounds.
Materials and Methods
Protein puriﬁcation and crystallization. The SULT1B1, SULT1C1,
SULT1C2, SULT1C3, and SULT4A1 genes were ampliﬁed by PCR
from the Mammalian Gene Collection clones and subcloned into a
modiﬁed pET28a-LIC vector. Expression and puriﬁcation of re-
combinant proteins was as described by Dombrovski et al. [17].
Puriﬁed recombinant proteins contained an additional Gly-Ser
dipeptide at the N-terminus. Additional details are provided at
http://www.sgc.utoronto.ca in the structure gallery for each protein.
Puriﬁed SULT1B1, SULT1C1, and SULT1C3 were crystallized in
the presence of 2 mM PAP using the hanging drop method at 20 8Cb y
mixing: for SULT1B1—2 ll of the protein solution with 2 ll of the
reservoir solution containing 0.1 M Bis-Tris (pH 6.5), 0.2 M
ammonium sulfate. and 16%–20% polyethylene glycol 4000; for
SULT1C1—2 ll of the protein solution with 2 ll of the reservoir
solution containing 0.1 M K2HPO4 and 12%–16% polyethylene glycol
3350; and for SULT1C3—2 ll of the protein solution with 2 ll of the
reservoir solution containing 18% polyethylene glycol 3350, 0.2 M
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SULT1C2-PAP-PCP ternary complex, 10 mg/ml of puriﬁed SULT1C2
was mixed with 2 mM PAP and 2 mM PCP in 20 mM MES-NaOH
buffer (pH 6.5), and incubated on ice for 30 min. SULT1C2-PAP-PCP
complex was crystallized using the sitting drop method at 20 8Cb y
mixing 0.8 ll of the protein-cofactor-inhibitor mix with 0.8 ll of the
reservoir solution containing 25% polyethylene glycol 3350, 0.2 M
lithium sulfate, 0.1 M Bis-Tris (pH 6.5). SULT4A1 and SULT1C2
crystals were obtained by using the hanging drop method at 20 8Cb y
mixing 2 ll of the protein solution with 2 ll of the reservoir solution
containing 20% polyethylene glycol 4000, 0.2 M ammonium tartrate,
and 14%–20% polyethylene glycol 3350, 0.2 M lithium citrate, 0.1 M
sodium citrate (pH 4.6), respectively.
Chemical library preparation. A library of 90 compounds was
created for screening sulfotransferases. These compounds were
known substrates, products, and inhibitors of sulfotransferases, their
analogs, and compounds with high similarity to known inhibitors
identiﬁed from the literature and public databases (http://www.rcsb.
org and http://www.brenda.uni-koeln.de). Certain substrates, such as
controlled substances, were not included, and some additional
compounds were selected through chemical similarity to known
SULT substrates and inhibitors using the ChemNavigator search
engine (http://www.chemnavigator.com/). The compounds were dis-
solved in 100% DMSO at 100 mM concentration and subsequently
diluted stepwise to 10 mM and 1 mM in Hepes buffer (100 mM Hepes,
150 mM NaCl [pH 7.5]). The full list of compounds in the library is
included in Table S2.
Ligand binding screens. Screening for ligand binding was
performed in 50-ll volume with a ﬁnal concentration of 1 mM of
compound per well, in 384-well plates. The concentration of protein
was the same for all wells at 0.4 mg/ml. Ligand binding was detected
by monitoring the increase in thermostability of proteins in the
presence of ligands. Protein thermostability at pH 7.5 was studied
using StarGazer technology that monitors protein stability by its
aggregation properties [20,21]. Protein samples at 0.4 mg/ml were
heated from 27 8Ct o8 08C at the rate of 0.5 8C per min in clear-
bottom 384-well plates (Nunc, http://www.nuncbrand.com/) in 50 llo f
100 mM Hepes (pH 7.5) and 150 mM NaCl. Protein aggregation was
monitored by capturing images of scattered light every 30 s with a
CCD (Charge-Coupled Device) camera. The pixel intensities in a pre-
selected region of each well were integrated to generate a value
representative of the total amount of scattered light in that region.
These total intensities were then plotted against temperature for
each sample well and ﬁt to the Boltzman equation by nonlinear
regression. The point of inﬂection of each ‘‘denaturation’’ curve was
identiﬁed as Tagg (aggregation temperature). The increase in stability
of the protein in the presence of a ligand is shown as DTagg.
Sulfotransferase activity screens. Enzyme assays were performed
using a HPLC-based method that we developed for sulfotransferase
activity assay by modifying the protocol previously used to monitor
ADP production and ATP hydrolysis by a puriﬁed bacterial ATPase
[41]. SULTs at 1–5 lM were assayed in the presence of 0.1 to 0.5 mM
PAPS and different concentrations of each substrate in 100 mM
Hepes (pH 7.5) by incubating the reaction at 37 8C for a period of
time from 15 to 120 min depending on how fast PAPS was converted
to PAP. The Km values for characterized sulfotransferases are in the
range of nanomolar to millimolar concentrations [24,42], with a
signiﬁcant variation in catalytic efﬁciency and substrate speciﬁcity.
Based on these observations and considering possible substrate
inhibition [19,43], we tested all sulfotransferases at substrate
concentrations of 10, 25, and 100 lM. The reactions were stopped
by adding two volumes of urea (ﬁnal concentration of 5.3 M), and the
mixture was ﬁltered through a 5-kDa molecular weight cutoff Amicon
Ultrafree-MC ﬁlter (Millipore, Bedford, Massachusetts, United States)
to remove the protein. The ratio of PAP and PAPS was determined
after separating them on HPLC using a 4.5 mm350 mm WP QUAT, a
strong ion-exchange column (J. T. Baker, Phillipsburg, New Jersey,
United States), using a gradient of triethylamine bicarbonate from 20
to 500 mM applied at 2 ml/min for 7 min. The progress of the reaction
was monitored by reading the absorbance at 259 nm, and the amount
of PAP produced was determined by integration of the resolved peaks
using the HPLC software (Waters, http://www.waters.com/). All values
in Table 2 were corrected for the rate of conversion of PAPS to PAP
in the presence of enzyme, but no substrate. This background activity
is reported for each SULT in the last row of Table 2, and the values
are the average of three independent measurements.
Sequence, structure, and data clustering analysis. Sequences used
to generate Figures 3 and 8 are as follows: SULT1A1, SULT1A2,
SULT1A3, SULT1A4, SULT1B1, SULT1C1, SULT1C2, SULT1C3,
SULT1E1, SULT2A1, SULT2B1, SULT4A1, and SULT6B1. We
created a multiple sequence alignment of the above-mentioned
sequences using HMMer [44] and the pfam [45] Sulfotransferase_1
(PF00685.15) Hidden Markov Model. Sequence similarity is measured
using the Tanimoto coefﬁcient of residues in common in the HMM-
based alignment. The calculation of local sequence similarities
involves the detection of binding site residues [46], and their
subsequent mapping onto the HMM-based alignment. Cofactor
(PAP/PAPS) binding residues were also mapped onto the alignment
and excluded from all pairwise comparisons and similarity calcu-
lations. Substrate binding-site structural similarities were detected
using a two-stage graph-matching process providing a one-to-one
chemical and spatial correspondence between atoms in clefts. The
method considers all non-hydrogen atoms and can use large sets of
atoms as input allowing larger, over-predicted and apo-form binding
sites to be analyzed. In the ﬁrst stage, the two clefts are superimposed
[47] via the detection of the largest clique [48] in a Ca association
graph corresponding to the largest subset of identical residues in
equivalent spatial locations. The ﬁrst stage is used to constrain the
construction of the second-stage all-atom association graph. The
second-stage graph-matching results in the detection of the largest
subset of heavy atoms of equivalent atoms types [49], and spatial
positions. Pairwise local structural similarity was calculated as a
Tanimoto coefﬁcient based on the size of the largest clique in the
second graph-matching stage. Dissimilarity matrices were derived
from the similarity measures described above. Pairwise experimental
catalytic and binding-proﬁle dissimilarity matrices were calculated as
the L2 distance of the vectors with the corresponding experimental
measurements. Hierarchical clustering was used to create the
clustering trees shown in Figure 8. The correlation between the
cophenetic matrix and the original dissimilarity matrix was used to
choose the linkage method that results in the most accurate
representation of the original data [50]. Average linkage was found
to be the clustering method of choice in all instances.
pKa calculations of polyphenol hydroxyl moiety. To assess the
extent to which the acidity of the hydroxyl moiety of hydroxylated
polychlorinated biphenols is related to their inhibitory strength, we
computed the pKa values of the 4-hydroxyl group for a series of
hydroxylated PCB analogs. This group of compounds and their
inhibitory effect on SULT1E1 were previously reported [36]. To this
end, we used the pKa calculator in the PC stand-alone version of the
ACD (http://www.acdlabs.com) suite of programs. Two clusters of
compounds, namely 4-OH-(2,3,4,5,6)Cl and 4-OH-(3,5)Cl, are identi-
ﬁed as outliers upon computing a linear regression on the relation-
ship (R
2 ¼ 0.57).
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Accession Numbers
The National Center for Biotechnology Information (http://www.ncbi.
nlm.nih.gov) Reference Sequence (RefSeq) accession numbers for the
proteins referred to in this paper are SULT1A1 (NP_803880),
SULT1A2 (NP_001045), SULT1A3 (NP_003157), SULT1A4
(NP_001017389), SULT1B1 (NP_055280), SULT1C1 (NP_789795),
SULT1C2 (NP_006579), SULT1C3 (NP_001008743), SULT1E1
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Human Cytosolic Sulfotransferases(NP_005411), SULT2A1 (NP_003158), SULT2B1 (NP_814444),
SULT4A1 (NP_055166), and SULT6B1 (NP_001027549).
The Mammalian Gene Collection (http://mgc.nci.nih.gov) clones
discussed in this paper are SULT1B1 (gi: 29550928), SULT1C1 (gi:
4507305), SULT1C2 (gi: 28830308), SULT1C3 (gi: 56847626), and
SULT4A1 (gi: 7657633).
The Protein Data Bank (http://www.pdb.org) IDs for the proteins
discussed in this paper are SULT1A3 (1CJM), SULT1C2 (2AD1),
SULT4A1 (1ZD1), SULT1C1 with PAP (2ETG), SULT1B1 with PAP
(1XV1), SULT1C3 with PAP (2H8K), SULT1A1 with PAP and p-
nitrophenol (1LS6), SULT2B1b with PAP and pregnenolone (1Q20),
S U L T 1 E 1w i t hP A Pa n d3 , 5 , 3 9,59-tetrachloro-biphenyl-4,49-diol
(1G3M), SULT2A1 with DHEA (1J99), SULT2A1 with PAP (1EFH),
SULT1C2 with PAP and PCP (2GWH), SULT1A3 with PAP and
dopamine (2A3R), SULT1A1 with PAP and estradiol (2D06),
SULT2A1 with androsterone (1OV4), SULT2B1a with PAP and 2-
[N-cyclohexylamino]ethane sulfonic acid (1Q1Q), and SULT2B1b
with PAP and DHEA (1Q22).
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